Stefan Leucht

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4757850/publications.pdf

Version: 2024-02-01

435 papers	41,925 citations	2322 98 h-index	2828 191 g-index
484 all docs	484 docs citations	484 times ranked	26179 citing authors

#	Article	IF	Citations
1	Associations between individual antipsychotics and the risk of arrests and convictions of violent and other crime: a nationwide within-individual study of 74 925 persons. Psychological Medicine, 2022, 52, 3792-3800.	4.5	8
2	How Efficacious Are Antipsychotic Drugs for Schizophrenia? An Interpretation Based on 13 Effect Size Indices. Schizophrenia Bulletin, 2022, 48, 27-36.	4.3	7
3	About the issue of including or excluding studies from China in systematic reviews. Schizophrenia Research, 2022, 240, 162-163.	2.0	4
4	Family interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. Lancet Psychiatry,the, 2022, 9, 211-221.	7.4	47
5	New insight into the CATIE study by constrained confidence partitioning. An innovative technique towards personalized antipsychotic drug therapy in schizophrenia treatment. Schizophrenia Research, 2022, 239, 192-199.	2.0	2
6	Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials. Schizophrenia Bulletin, 2022, 48, 643-654.	4.3	35
7	Which first-generation antipsychotics should be â€œrepurposedâ€•for the treatment of schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 1-3.	3.2	10
8	Early- and subsequent- response of cognitive functioning in Alzheimer's disease: Individual-participant data from five pivotal randomized clinical trials of donepezil. Journal of Psychiatric Research, 2022, 148, 159-164.	3.1	5
9	Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials. JAMA Psychiatry, 2022, 79, 210.	11.0	47
10	Cognitive impairment networks in Alzheimer's disease: Analysis of three double-blind randomized, placebo-controlled, clinical trials of donepezil. European Neuropsychopharmacology, 2022, 57, 50-58.	0.7	2
11	Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 201-219.	2.2	3
12	Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet, The, 2022, 399, 824-836.	13.7	88
13	Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis. Molecular Autism, 2022, 13, 10.	4.9	36
14	Concept of the Munich/Augsburg Consortium Precision in Mental Health for the German Center of Mental Health. Frontiers in Psychiatry, 2022, 13, 815718.	2.6	2
15	Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis. Lancet Psychiatry,the, 2022, 9, 232-242.	7.4	15
16	Relapse prevention in schizophrenia â€“ Authors' reply. Lancet Psychiatry,the, 2022, 9, e14.	7.4	0
17	Confidence of evidence should be considered in ranking of treatments in the network meta-analysis â€“ Authors' reply. Lancet Psychiatry,the, 2022, 9, e16.	7.4	0
18	Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial. Lancet Psychiatry,the, 2022, 9, 291-306.	7.4	6

#	Article	IF	Citations
19	Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends. Neuroscience and Biobehavioral Reviews, 2022, 136, 104608.	6.1	67
20	Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art. Schizophrenia Research: Cognition, 2022, 29, 100249.	1.3	23
21	Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia. Schizophrenia Bulletin, 2022, 48, 774-784.	4.3	9
22	Maintenance Treatment With Antipsychotic Drugs in Schizophrenia: A Cochrane Systematic Review and Meta-analysis. Schizophrenia Bulletin, 2022, 48, 738-740.	4.3	13
23	Scalability of the Positive and Negative Syndrome Scale in firstâ€episode schizophrenia assessed by Rasch models. Acta Psychiatrica Scandinavica, 2022, 146, 21-35.	4.5	4
24	What Is the Minimum Clinically Important Change in Negative Symptoms of Schizophrenia? PANSS Based Post-hoc Analyses of a Phase III Clinical Trial. Frontiers in Psychiatry, 2022, 13, 816339.	2.6	4
25	Cognitive behavioural therapy plus standard care for first episode psychosis. The Cochrane Library, 2022, 2022, .	2.8	1
26	Vitruvian plot: a visualisation tool for multiple outcomes in network meta-analysis. Evidence-Based Mental Health, 2022, 25, e65-e70.	4.5	8
27	Effects of antipsychotics on heart rate in treatment of schizophrenia: a systematic review and meta-analysis. Therapeutic Advances in Psychopharmacology, 2022, 12, 204512532210972.	2.7	3
28	Evidence-based Shared-Decision-Making Assistant (SDM-assistant) for choosing antipsychotics: protocol of a cluster-randomized trial in hospitalized patients with schizophrenia. BMC Psychiatry, 2022, 22, .	2.6	2
29	Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs. Pharmacopsychiatry, 2022, 55, 233-245.	3.3	9
30	Antipsychotic drugs: from â€˜major tranquilizersâ€™ to Neuroscience-based-Nomenclature. Psychological Medicine, 2021, 51, 522-524.	4.5	10
31	Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 293-302.	3.2	20
32	Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure. JAMA Psychiatry, 2021, 78, 270.	11.0	91
33	Treatment Goals for Patients with Schizophrenia â€" A Narrative Review of Physician and Patient Perspectives. Pharmacopsychiatry, 2021, 54, 53-59.	3.3	4
34	Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study. Schizophrenia Bulletin, 2021, 47, 672-681.	4.3	4
35	Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study. European Psychiatry, 2021, 64, e7.	0.2	15
36	Quantifying the heterogeneity of cognitive functioning in Alzheimerâ€™s disease to extend the placebo-treatment dichotomy: Latent class analysis of individual-participant data from five pivotal randomized clinical trials of donepezil. European Psychiatry, 2021, 64, e16.	0.2	1

#	Article	IF	Citations
37	Multifactorial barriers in the implementation of schizophrenia and psychosocial therapies guidelines: A quantitative study across different professions. Schizophrenia Research, 2021, 228, 425-434.	2.0	10
38	Antipsychotic Medications: Enhancing Use to Improve Outcomes. Schizophrenia Bulletin, 2021, 47, 1201-1204.	4.3	2
39	A living meta-ecological study of the consequences of the COVID-19 pandemic on mental health. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 219-221.	3.2	10
40	Short-acting intramuscular second-generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders. A systematic review and network meta-analysis. Schizophrenia Research, 2021, 229, 3-11.	2.0	7
41	An efficient way to assess the effect of COVID-19 on mental health in the general population. Lancet Psychiatry,the, 2021, 8, e14-e15.	7.4	10
42	The role of depression in the prediction of a â€œlateâ€•remission in first-episode psychosis: An analysis of the OPTiMiSE study. Schizophrenia Research, 2021, 231, 100-107.	2.0	4
43	Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients. Frontiers in Pharmacology, 2021, 12, 688950.	3.5	14
44	Lower cholinergic basal forebrain volumes link with cognitive difficulties in schizophrenia. Neuropsychopharmacology, 2021, 46, 2320-2329.	5.4	17
45	Let us not rush back to odds ratios without a recommendation to convert them to interpretable measures. Journal of Clinical Epidemiology, 2021, 134, 172-173.	5.0	0
46	Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder. Brain Sciences, 2021, 11, 908.	2.3	4
47	Metabolic side effects of antipsychotic drugs in individuals with schizophrenia during medium- to long-term treatment: protocol for a systematic review and network meta-analysis of randomized controlled trials. Systematic Reviews, 2021, 10, 214.	5.3	5
48	Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia. JAMA Psychiatry, 2021, 78, 1238.	11.0	44
49	Evaluating pimavanserin as a treatment for psychiatric disorders: A pharmacological property in search of an indication. Expert Opinion on Pharmacotherapy, 2021, 22, 1651-1660.	1.8	8
50	Examining Side Effect Variability of Antipsychotic Treatment in Schizophrenia Spectrum Disorders: A Meta-analysis of Variance. Schizophrenia Bulletin, 2021, 47, 1601-1610.	4.3	6
51	Linking the Clinical Dementia Rating Scale-Sum of Boxes, the Clinicianâ€™s Interview-Based Impression Plus Caregiver Input, and the Clinical Global Impression Scale: Evidence based on Individual Participant Data from Five Randomized Clinical Trials of Donepezil. Journal of Alzheimer's Disease, 2021, 82, 1075-1084.	2.6	5
52	Should â€˜typicalâ€™, first-generation antipsychotics no longer be generally used in the treatment of schizophrenia?. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 1411-1413.	3.2	6
53	Efficacy and safety of clozapine in psychotic disordersâ€”a systematic quantitative meta-review. Translational Psychiatry, 2021, 11, 487.	4.8	61
54	Clozapine, Long-Acting Injectables (and Polypharmacy?) Superior in U.S. and International Registries. American Journal of Psychiatry, 2021, 178, 888-889.	7.2	5

#	Article	IF	Citations
55	Prolactin levels influenced by antipsychotic drugs in schizophrenia: A systematic review and network meta-analysis. Schizophrenia Research, 2021, 237, 20-25.	2.0	22
56	Matrix Metalloproteinase 9 Blood Alterations in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis. Schizophrenia Bulletin, 2021, 47, 986-996.	4.3	9
57	Linking the Mini-Mental State Examination, the Alzheimerâ€™s Disease Assessment Scaleâ€“Cognitive Subscale and the Severe Impairment Battery: evidence from individual participant data from five randomised clinical trials of donepezil. Evidence-Based Mental Health, 2021, 24, 56-61.	4.5	14
58	Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. Lancet Psychiatry,the, 2021, 8, 969-980.	7.4	114
59	Limitations in Research on Maintenance Treatment for Individuals With Schizophreniaâ€”Reply. JAMA Psychiatry, 2021, , .	11.0	0
60	Translating the BDI and BDI-II into the HAMD and vice versa with equipercentile linking. Epidemiology and Psychiatric Sciences, 2020, 29, e24.	3.9	39
61	Antipsychotic drugs v. barbiturates or benzodiazepines used as active placebos for schizophrenia: a systematic review and meta-analysis. Psychological Medicine, 2020, 50, 2622-2633.	4.5	6
62	A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 83-94.	3.2	4
63	Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. American Journal of Psychiatry, 2020, 177, 342-353.	7.2	137
64	M201. MODERATORS OF WEIGHT GAIN IN RANDOMIZED CONTROLLED TRIALS OF SCHIZOPHRENIA â€“ A META-REGRESSION ANALYSIS. Schizophrenia Bulletin, 2020, 46, S212-S213.	4.3	0
65	Hostility and aggressive behaviour in first episode psychosis: Results from the OPTiMiSE trial. Schizophrenia Research, 2020, 223, 271-278.	2.0	9
66	Optimal Dose of Selective Serotonin Reuptake Inhibitors, Venlafaxine, and Mirtazapine in Major Depression: A Systematic Review and Dose-Response Meta-Analysis. Focus (American Psychiatric) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50		
67	What is the â€œbest introâ€â€”explanatory versus pragmatic antipsychotic drug trials. Lancet Psychiatry,the, 2020, 7, 1004-1006.	7.4	4
68	Maintenance treatment with antipsychotic drugs for schizophrenia. The Cochrane Library, 2020, 2020, CD008016.	2.8	56
69	Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis. Molecular Autism, 2020, 11, 66.	4.9	40
70	Aberrant striatal dopamine links topographically with cortico-thalamic dysconnectivity in schizophrenia. Brain, 2020, 143, 3495-3505.	7.6	20
71	Antipsychotic Dose in Acute Schizophrenia: A Meta-analysis. Schizophrenia Bulletin, 2020, 46, 1439-1458.	4.3	22
72	Rasch analysis of the PANSS negative subscale and exploration of negative symptom trajectories in first-episode schizophrenia â€“ data from the OPTiMiSE trial. Psychiatry Research, 2020, 289, 112970.	3.3	11

#	Article	IF	Citations
73	Gauging the Scope for Precision Medicine: Evaluating Individual Differences in Side Effects to Antipsychotic Treatment. Biological Psychiatry, 2020, 87, S291-S292.	1.3	0
74	T200. METABOLIC SIDE EFFECTS OF ANTIPSYCHOTIC DRUGS â€“ PROTOCOL OF A SYSTEMATIC REVIEW AND NETWORK- METAANALYSIS. Schizophrenia Bulletin, 2020, 46, S308-S308.	4.3	0
75	Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. Lancet Psychiatry,the, 2020, 7, 581-601.	7.4	176
76	Antipsychotics for schizophrenia and substance misuse â€“ Authors' reply. Lancet, The, 2020, 395, 1903.	13.7	1
77	Are Randomized Controlled Trials on Pharmacotherapy and Psychotherapy for Positive Symptoms of Schizophrenia Comparable? A Systematic Review of Patient and Study Characteristics. Schizophrenia Bulletin, 2020, 46, 496-504.	4.3	11
78	How well do elderly patients with major depressive disorder respond to antidepressants: a systematic review and single-group meta-analysis. BMC Psychiatry, 2020, 20, 102.	2.6	30
79	Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial. Contemporary Clinical Trials Communications, 2020, 17, 100537.	1.1	17
80	Persistent negative symptoms in recent-onset psychosis: Relationship to treatment response and psychosocial functioning. European Neuropsychopharmacology, 2020, 34, 76-86.	0.7	30
81	Psychosocial treatments for relapse prevention in schizophrenia: study protocol for a systematic review and network meta-analysis of randomised evidence. BMJ Open, 2020, 10, e035073.	1.9	3
82	Comparative Efficacy and Tolerability of 32 Oral Antipsychotics for the Acute Treatment of Adults With Multi-Episode Schizophrenia: A Systematic Review and Network Meta-Analysis. Focus (American) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.8	28
83	How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials. Schizophrenia Bulletin, 2019, 45, 639-646.	4.3	74
84	Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis. Lancet Psychiatry,the, 2019, 6, 753-765.	7.4	29
85	Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis. Neuropsychopharmacology, 2019, 44, 1955-1966.	5.4	23
86	Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet, The, 2019, 394, 939-951.	13.7	1,050
87	Efficacy and tolerability of pharmacological and non-pharmacological interventions in older patients with major depressive disorder: A systematic review, pairwise and network meta-analysis. European Neuropsychopharmacology, 2019, 29, 1003-1022.	0.7	50
88	Optimal dosing of antidepressant drugs â€“ Authors' reply. Lancet Psychiatry,the, 2019, 6, 806-807.	7.4	1
89	Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study. Translational Psychiatry, 2019, 9, 20.	4.8	52
90	Evaluation of Differences in Individual Treatment Response in Schizophrenia Spectrum Disorders. JAMA Psychiatry, 2019, 76, 1063.	11.0	48

#	Article	IF	Citations
91	Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry,the, 2019, 6, 601-609.	7.4	184
92	17.1 PREDICTORS OF RELAPSE IN FIRST EPISODE PSYCHOSIS PATIENTS IN REMISSION. Schizophrenia Bulletin, 2019, 45, S115-S116.	4.3	0
93	The controversy about cognitive behavioural therapy for schizophrenia. World Psychiatry, 2019, 18, 235-236.	10.4	22
94	Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms. Brain, 2019, 142, 1813-1826.	7.6	46
95	Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia. Neuropsychopharmacology, 2019, 44, 1589-1596.	5.4	26
96	17.4 STRATIFICATION AND PREDICTION OF REMISSION IN FIRST-EPISODE PSYCHOSIS PATIENTS: THE OPTiMISE COHORT STUDY. Schizophrenia Bulletin, 2019, 45, S116-S117.	4.3	0
97	Efficient two-step multivariate random effects meta-analysis of individual participant data for longitudinal clinical trials using mixed effects models. BMC Medical Research Methodology, 2019, 19, 33.	3.1	6
98	Specific Substantial Dysconnectivity in Schizophrenia: A Transdiagnostic Multimodal Meta-analysis of Resting-State Functional and Structural Magnetic Resonance Imaging Studies. Biological Psychiatry, 2019, 85, 573-583.	1.3	93
99	Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis. European Neuropsychopharmacology, 2019, 29, 32-45.	0.7	59
100	Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis. Psychopharmacology, 2019, 236, 545-559.	3.1	33
101	Fat Mass and Obesity-Related Gene Variants rs9939609 and rs7185735 are Associated with Second-Generation Antipsychotic-Induced Weight Gain. Pharmacopsychiatry, 2019, 52, 16-23.	3.3	6
102	Schizophrenien und andere psychotische StÃ¶rungen. , 2019, , 301-362.e7.		1
103	Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet, The, 2018, 391, 1357-1366.	13.7	2,076
104	Enthusiasm and Skepticism About Using National Registers to Analyze Psychotropic Drug Outcomes. JAMA Psychiatry, 2018, 75, 314.	11.0	7
105	Initial severity of major depression and efficacy of new generation antidepressants: individual participant data metaâ€analysis. Acta Psychiatrica Scandinavica, 2018, 137, 450-458.	4.5	39
106	Antidepressants might work for people with major depression: where do we go from here?. Lancet Psychiatry,the, 2018, 5, 461-463.	7.4	23
107	Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 625-639.	3.2	143
108	Is placebo response in antidepressant trials rising or not? A reanalysis of datasets to conclude this long-lasting controversy. Evidence-Based Mental Health, 2018, 21, 1-3.	4.5	27

#	Article	IF	Citations
109	Psychological interventions for positive symptoms in schizophrenia: protocol for a network meta-analysis of randomised controlled trials. BMJ Open, 2018, 8, e019280.	1.9	8
110	Dose equivalents for second generation long-acting injectable antipsychotics: The minimum effective dose method. Schizophrenia Research, 2018, 193, 23-28.	2.0	34
111	Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies. Schizophrenia Bulletin, 2018, 44, 603-619.	4.3	137
112	Translating the HAM-D into the MADRS and vice versa with equipercentile linking. Journal of Affective Disorders, 2018, 226, 326-331.	4.1	62
113	Auditory hallucinations across the lifespan: a systematic review and meta-analysis. Psychological Medicine, 2018, 48, 879-888.	4.5	110
114	Clozapine versus olanzapine for people with schizophrenia. The Cochrane Library, 2018, , .	2.8	1
115	Clozapine versus quetiapine for people with schizophrenia. The Cochrane Library, 2018, , .	2.8	0
116	Clozapine versus risperidone for people with schizophrenia. The Cochrane Library, 2018, , .	2.8	0
117	S47. ADD-ON SPIRONOLACTONE FOR THE TREATMENT OF SCHIZOPHRENIA (SPIRO TREAT). Schizophrenia Bulletin, 2018, 44, S342-S342.	4.3	0
118	Response rates in patients with schizophrenia and positive symptoms receiving cognitive behavioural therapy: a systematic review and single-group meta-analysis. BMC Psychiatry, 2018, 18, 380.	2.6	23
119	Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. Focus (American) Tj ETQq1 1 0.784314 rgBT /Over		
120	Clozapine as a firstâ€•or secondâ€line treatment in schizophrenia: a systematic review and metaâ€analysis. Acta Psychiatrica Scandinavica, 2018, 138, 281-288.	4.5	56
121	Psychological interventions to reduce positive symptoms in schizophrenia: systematic review and network metaâ€analysis. World Psychiatry, 2018, 17, 316-329.	10.4	119
122	Antipsychotic drugs for elderly patients with schizophrenia: A systematic review and meta-analysis. European Neuropsychopharmacology, 2018, 28, 1360-1370.	0.7	28
123	Tardive dyskinesia risk with firstâ€•and secondâ€generation antipsychotics in comparative randomized controlled trials: a metaâ€analysis. World Psychiatry, 2018, 17, 330-340.	10.4	117
124	Possibly no baseline severity effect for antidepressants versus placebo but for antipsychotics. Why?. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 621-623.	3.2	4
125	60â€¯years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Meta-regression of predictors of placebo response. Schizophrenia Research, 2018, 201, 315-323.	2.0	26
126	Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis. European Neuropsychopharmacology, 2018, 28, 659-674.	0.7	93

#	Article	IF	Citations
127	Is there compelling evidence that schizophrenia longâ€term treatment guidelines should be changed?. World Psychiatry, 2018, 17, 166-167.	10.4	10
128	Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials. Lancet Psychiatry,the, 2018, 5, 653-663.	7.4	58
129	Increasing antipsychotic dose for non response in schizophrenia. The Cochrane Library, 2018, 5, CD011883.	2.8	8
130	Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. The Cochrane Library, 2018, 5, CD011884.	2.8	4
131	Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry,the, 2018, 5, 797-807.	7.4	141
132	31.3 CLINICAL UTILITY OF MRI SCANNING IN FIRST EPISODE PSYCHOSIS. Schizophrenia Bulletin, 2018, 44, S50-S51.	4.3	2
133	In Reply. Deutsches Ärzteblatt International, 2018, 115, 68-69.	0.9	0
134	What does the MADRS mean? Equipercentile linking with the CGI using a company database of mirtazapine studies. Journal of Affective Disorders, 2017, 210, 287-293.	4.1	45
135	Combining randomized and nonâ€randomized evidence in network metaâ€analysis. Statistics in Medicine, 2017, 36, 1210-1226.	1.6	110
136	Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, metaâ€analysis and metaâ€regression analysis. World Psychiatry, 2017, 16, 77-89.	10.4	156
137	Schizophrenia, primary negative symptoms, and soft outcomes in psychiatry. Lancet, The, 2017, 389, 1077-1078.	13.7	16
138	Î˚ Markov model for longitudinal studies with incomplete dichotomous outcomes. Pharmaceutical Statistics, 2017, 16, 122-132.	1.3	3
139	Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia. JAMA Psychiatry, 2017, 74, 675.	11.0	153
140	Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. American Journal of Psychiatry, 2017, 174, 927-942.	7.2	338
141	Clozapine in treatment-resistant schizophrenia. British Journal of Psychiatry, 2017, 210, 299-299.	2.8	4
142	A novel approach to measuring response and remission in schizophrenia in clinical trials. Schizophrenia Research, 2017, 190, 123-128.	2.0	6
143	DSM-III-R change in definition might have affected placebo response to antidepressants â€“ Authors' reply. Lancet Psychiatry,the, 2017, 4, 22-23.	7.4	1
144	Living systematic reviews: 4. Living guideline recommendations. Journal of Clinical Epidemiology, 2017, 91, 47-53.	5.0	184

#	Article	IF	Citations
145	Living systematic review: 1. Introductionâ€"the why, what, when, and how. Journal of Clinical Epidemiology, 2017, 91, 23-30.	5.0	406
146	Living systematic reviews: 2. Combining human and machine effort. Journal of Clinical Epidemiology, 2017, 91, 31-37.	5.0	246
147	Initial symptom severity of bipolar I disorder and the efficacy of olanzapine: a meta-analysis of individual participant data from five placebo-controlled studies. Lancet Psychiatry,the, 2017, 4, 859-867.	7.4	23
148	Living systematic reviews: 3. Statistical methods for updating meta-analyses. Journal of Clinical Epidemiology, 2017, 91, 38-46.	5.0	102
149	Do antipsychotic drugs lose their efficacy for relapse prevention over time?. British Journal of Psychiatry, 2017, 211, 127-129.	2.8	29
150	Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry,the, 2017, 4, 694-705.	7.4	97
151	Clinical relevance of findings in trials of CBT for depression. European Psychiatry, 2017, 45, 207-211.	0.2	28
152	Common pitfalls and mistakes in the set-up, analysis and interpretation of results in network meta-analysis: what clinicians should look for in a published article. Evidence-Based Mental Health, 2017, 20, 88-94.	4.5	66
153	Comparative efficacy and acceptability of antidepressants, psychological interventions, and their combination for depressive disorder in children and adolescents: protocol for a network meta-analysis. BMJ Open, 2017, 7, e016608.	1.9	18
154	How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis. European Neuropsychopharmacology, 2017, 27, 835-844.	0.7	92
155	Do antipsychotics lead to cognitive impairment in dementia? A meta-analysis of randomised placebo-controlled trials. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 187-198.	3.2	14
156	The Prevalence of Mental Illness in Homeless People in Germany. Deutsches Ärzteblatt International, 2017, 114, 665-672.	0.9	56
157	EvidenzbasierungÃ¼ und leitliniengestÃ¼tzte Therapie in der Psychiatrie. , 2017, , 1321-1338.		0
158	Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis. BMJ Open, 2016, 6, e010919.	1.9	139
159	Effects of Short-Term Exercise Interventions on Behavioral and Psychological Symptoms in Patients with Dementia: AÂSystematic Review. Journal of Alzheimer's Disease, 2016, 55, 1583-1594.	2.6	32
160	Biological v. psychosocial treatments: a myth about pharmacotherapy v. psychotherapy. British Journal of Psychiatry, 2016, 208, 309-311.	2.8	33
161	Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach. Lancet Psychiatry,the, 2016, 3, 935-946.	7.4	144
162	Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies. Lancet Psychiatry,the, 2016, 3, 1059-1066.	7.4	161

#	Article	IF	Citations
163	Authors' reply. British Journal of Psychiatry, 2016, 209, 171-172.	2.8	0
164	Use of Clozapine in Schizophreniaâ€"Reply. JAMA Psychiatry, 2016, 73, 1098.	11.0	0
165	Dose Equivalents for Antipsychotic Drugs: The DDD Method: Table 1.. Schizophrenia Bulletin, 2016, 42, S90-S94.	4.3	428
166	Valproate for schizophrenia. The Cochrane Library, 2016, 2016, CD004028.	2.8	65
167	Identifying a system of predominant negative symptoms: Network analysis of three randomized clinical trials. Schizophrenia Research, 2016, 178, 17-22.	2.0	49
168	Network meta-analyses should be the highest level of evidence in treatment guidelines. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 477-480.	3.2	133
169	The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for Its Methodology and a Review of the Effectiveness of Switching Antipsychotics. Focus (American) Tj ETQq1 1 0.784314 rgBT /Ove		
170	Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet, The, 2016, 388, 881-890.	13.7	513
171	Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis. American Journal of Psychiatry, 2016, 173, 876-886.	7.2	167
172	Second-generation antipsychotics and quality of life in schizophrenia. Lancet Psychiatry,the, 2016, 3, 694-695.	7.4	4
173	Using the contribution matrix to evaluate complex study limitations in a network meta-analysis: a case study of bipolar maintenance pharmacotherapy review. BMC Research Notes, 2016, 9, 218.	1.4	17
174	The Longitudinal Course of Schizophrenia Across the Lifespan. Harvard Review of Psychiatry, 2016, 24, 118-128.	2.1	112
175	Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia. JAMA Psychiatry, 2016, 73, 199.	11.0	235
176	Initial severity and efficacy of risperidone in autism: Results from the RUPP trial. European Psychiatry, 2016, 32, 16-20.	0.2	20
177	Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials. World Journal of Biological Psychiatry, 2016, 17, 210-220.	2.6	4
178	The SWITCH study: rationale and design of the trial. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 513-521.	3.2	7
179	Publication bias and small-study effects magnified effectiveness of antipsychotics but their relative ranking remained invariant. Journal of Clinical Epidemiology, 2016, 69, 161-169.	5.0	25
180	Behandlungsresistenz. , 2016, , 157-176.		2

#	Article	IF	Citations
181	Evidenzbasierung und leitliniengeschÃ¼tzte Therapie in der Psychiatrie. , 2016, , 1-18.		0
182	Perphenazine for schizophrenia. The Cochrane Library, 2015, 2015, CD003443.	2.8	15
183	How effective are common medications: a perspective based on meta-analyses of major drugs. BMC Medicine, 2015, 13, 253.	5.5	77
184	Switching antipsychotic for non response in schizophrenia. The Cochrane Library, 2015, , .	2.8	0
185	Accounting for uncertainty due to â€˜last observation carried forwardâ€™ outcome imputation in a metaâ€analysis model. Statistics in Medicine, 2015, 34, 742-752.	1.6	4
186	Lithium for schizophrenia. The Cochrane Library, 2015, 2015, CD003834.	2.8	57
187	Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. The Cochrane Library, 2015, , .	2.8	2
188	Initial Severity of Schizophrenia and Efficacy of Antipsychotics. JAMA Psychiatry, 2015, 72, 14.	11.0	94
189	Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. American Journal of Psychiatry, 2015, 172, 617-629.	7.2	150
190	Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes. Pharmacogenomics, 2015, 16, 5-22.	1.3	15
191	Defining therapeutic benefit for people with schizophrenia: Focus on negative symptoms. Schizophrenia Research, 2015, 162, 169-174.	2.0	26
192	Secondâ€generation antipsychotic effect on cognition in patients with schizophreniaâ€”a metaâ€analysis of randomized clinical trials. Acta Psychiatrica Scandinavica, 2015, 131, 185-196.	4.5	216
193	Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. The Cochrane Library, 2015, 2015, CD009831.	2.8	52
194	Detecting Neuroimaging Biomarkers for Schizophrenia: A Meta-Analysis of Multivariate Pattern Recognition Studies. Neuropsychopharmacology, 2015, 40, 1742-1751.	5.4	182
195	Joint modeling of dropout and outcome in three pivotal clinical trials of schizophrenia. Schizophrenia Research, 2015, 164, 122-126.	2.0	8
196	Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. Journal of Affective Disorders, 2015, 180, 179-184.	4.1	267
197	Modeling Determinants of Medication Attitudes and Poor Adherence in Early Nonaffective Psychosis: Implications for Intervention. Schizophrenia Bulletin, 2015, 41, 584-596.	4.3	36
198	The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for its Methodology and a Review of the Effectiveness of Switching Antipsychotics. Schizophrenia Bulletin, 2015, 41, 549-558.	4.3	47

#	Article	IF	Citations
199	CYP1A2*1D and *1F Polymorphisms Have a Significant Impact on Olanzapine Serum Concentrations. Therapeutic Drug Monitoring, 2015, 37, 152-160.	2.0	31
200	Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose Method. Schizophrenia Bulletin, 2015, 41, 1397-1402.	4.3	198
201	Recent meta-analyses neglect previous systematic reviews and meta-analyses about the same topic: a systematic examination. BMC Medicine, 2015, 13, 82.	5.5	46
202	Schizophrenien und andere psychotische StÃ¶rungen. , 2015, , 349-412.		0
203	Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. The Cochrane Library, 2014, 2014, CD009268.	2.8	31
204	Carbamazepine for schizophrenia. The Cochrane Library, 2014, , CD001258.	2.8	26
205	Comparative Efficacy and Tolerability of 15 Antipsychotic Drugs in Schizophrenia: A Multiple-Treatments Meta-Analysis. Focus (American Psychiatric Publishing), 2014, 12, 192-204.	0.8	1
206	Do patients with paranoid and disorganized schizophrenia respond differently to antipsychotic drugs?. Acta Psychiatrica Scandinavica, 2014, 130, 40-45.	4.5	5
207	Equipercentile linking of scales measuring functioning and symptoms: Examining the GAF, SOFAS, CGI-S, and PANSS. European Neuropsychopharmacology, 2014, 24, 1767-1772.	0.7	48
208	An approach for modelling multiple correlated outcomes in a network of interventions using odds ratios. Statistics in Medicine, 2014, 33, 2275-2287.	1.6	40
209	A systematic review of the clinical relevance of repetitive transcranial magnetic stimulation. Acta Psychiatrica Scandinavica, 2014, 130, 326-341.	4.5	39
210	Efficacy of Pharmacotherapy and Psychotherapy for Adult Psychiatric Disorders. JAMA Psychiatry, 2014, 71, 706.	11.0	244
211	Pharmacotherapy in the treatment of patients with borderline personality disorder. International Clinical Psychopharmacology, 2014, 29, 224-228.	1.7	28
212	Early improvement as a predictor of treatment response and remission in patients with schizophrenia: A pooled, post-hoc analysis from the asenapine development program. Journal of Psychopharmacology, 2014, 28, 387-394.	4.0	29
213	Addressing missing outcome data in meta-analysis. Evidence-Based Mental Health, 2014, 17, 85-89.	4.5	63
214	Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials. Schizophrenia Bulletin, 2014, 40, 192-213.	4.3	332
215	Aripiprazole versus other atypical antipsychotics for schizophrenia. The Cochrane Library, 2014, , CD006569.	2.8	70
216	Bipolar treatment efficacy â€“ Authors' reply. Lancet Psychiatry,the, 2014, 1, 418-419.	7.4	0

#	Article	IF	Citations
217	Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. Evidence-Based Mental Health, 2014, 17, 33-37.	4.5	89
218	Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. The Cochrane Library, 2014, , CD009369.	2.8	7
219	Polymorphisms in Serotonergic Pathways Influence the Outcome of Antidepressant Therapy in Psychiatric Inpatients. Genetic Testing and Molecular Biomarkers, 2014, 18, 20-31.	0.7	29
220	Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia. The Cochrane Library, 2014, , CD009396.	2.8	12
221	Efficacy of Anti-inflammatory Agents to Improve Symptoms in Patients With Schizophrenia: An Update. Schizophrenia Bulletin, 2014, 40, 181-191.	4.3	288
222	Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry,the, 2014, 1, 351-359.	7.4	280
223	Chlorpromazine versus every other antipsychotic for schizophrenia: A systematic review and meta-analysis challenging the dogma of equal efficacy of antipsychotic drugs. European Neuropsychopharmacology, 2014, 24, 1046-1055.	0.7	22
224	Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: Analysis of amisulpride vs placebo in three clinical trials. Schizophrenia Research, 2014, 156, 107-114.	2.0	18
225	Dose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method. Schizophrenia Bulletin, 2014, 40, 314-326.	4.3	277
226	META-ANALYSES ON DOUBLE-BLIND RCTS ADDING DRUGS WITH ANTI-INFLAMMATORY PROPERTIES TO ANTIPSYCHOTIC MEDICATION. Schizophrenia Research, 2014, 153, S15-S16.	2.0	0
227	Measurements of Response, Remission, and Recovery in Schizophrenia and Examples for Their Clinical Application. Journal of Clinical Psychiatry, 2014, 75, 8-14.	2.2	113
228	Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. The Cochrane Library, 2014, 2014, CD009230.	2.8	17
229	Perazine for schizophrenia. The Cochrane Library, 2014, 2014, CD002832.	2.8	5
230	Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia. The Cochrane Library, 2014, , CD009227.	2.8	5
231	Aripiprazole versus other atypical antipsychotics for schizophrenia. , 2013, , CD006569.		18
232	Imputation of response rates from means and standard deviations in schizophrenia. Schizophrenia Research, 2013, 151, 209-214.	2.0	22
233	Clozapine resistanceâ€"Augmentation strategies. European Neuropsychopharmacology, 2013, 23, 338.	0.7	6
234	Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophrenia Research, 2013, 150, 328-333.	2.0	46

#	Article	IF	Citations
235	The impact of trial characteristics on premature discontinuation of antipsychotics in schizophrenia. European Neuropsychopharmacology, 2013, 23, 1010-1016.	0.7	12
236	Efficacy of antipsychotic drugs for schizophrenia â€“ Authors' reply. Lancet, The, 2013, 382, 1874-1875.	13.7	6
237	Psychiatrists' decision making between branded and generic drugs. European Neuropsychopharmacology, 2013, 23, 686-690.	0.7	16
238	The Deceleration Capacity - a New Measure of Heart Rate Variability Evaluated in Patients With Schizophrenia and Antipsychotic Treatment. European Psychiatry, 2013, 28, 81-86.	0.2	27
239	Attaining and sustaining remission of predominant negative symptoms. Schizophrenia Research, 2013, 143, 60-64.	2.0	13
240	Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms. Schizophrenia Research, 2013, 145, 125-127.	2.0	34
241	Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: A meta-analysis and cochrane review of randomized controlled trials. European Neuropsychopharmacology, 2013, 23, 1023-1033.	0.7	63
242	Can we inflate effect size and thus increase chances of producing â€œpositiveâ€•results if we raise the baseline threshold in schizophrenia trials?. Schizophrenia Research, 2013, 144, 105-108.	2.0	0
243	Psychometric analysis in support of shortening the Scale for the Assessment of Negative Symptoms. European Neuropsychopharmacology, 2013, 23, 1051-1056.	0.7	18
244	Equipercentile linking of the BPRS and the PANSS. European Neuropsychopharmacology, 2013, 23, 956-959.	0.7	101
245	What does the HAMD mean?. Journal of Affective Disorders, 2013, 148, 243-248.	4.1	152
246	Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet, The, 2013, 382, 951-962.	13.7	2,094
247	Quetiapine versus other atypical antipsychotics for schizophrenia. The Cochrane Library, 2013, , CD006625.	2.8	44
248	Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Molecular Psychiatry, 2013, 18, 53-66.	7.9	136
249	Increasing Placebo Response in Antipsychotic Drug Trials: Letâ€™s Stop the Vicious Circle. American Journal of Psychiatry, 2013, 170, 1232-1234.	7.2	14
250	Association of the Common MC4R rs17782313 Polymorphism With Antipsychotic-Related Weight Gain. Journal of Clinical Psychopharmacology, 2013, 33, 74-79.	1.4	32
251	MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?. International Journal of Neuropsychopharmacology, 2013, 16, 2103-2109.	2.1	40
252	Evaluating the impact of imputations for missing participant outcome data in a network meta-analysis. Clinical Trials, 2013, 10, 378-388.	1.6	37

#	Article	IF	Citations
253	Pharmacological Augmentation Strategies for Schizophrenia Patients With Insufficient Response to Clozapine: A Quantitative Literature Review. Schizophrenia Bulletin, 2012, 38, 1003-1011.	4.3	144
254	Benzodiazepines for schizophrenia. The Cochrane Library, 2012, 11, CD006391.	2.8	66
255	Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. British Journal of Psychiatry, 2012, 200, 97-106.	2.8	332
256	Caregivers of patients with frontotemporal lobar degeneration: a review of burden, problems, needs, and interventions. International Psychogeriatrics, 2012, 24, 1368-1386.	1.0	56
257	Amitriptyline versus placebo for major depressive disorder. The Cochrane Library, 2012, 12, CD009138.	2.8	32
258	Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet, The, 2012, 379, 2063-2071.	13.7	742
259	Antipsychotic drugs for relapse prevention in schizophrenia â€“ Authors' reply. Lancet, The, 2012, 380, 1056.	13.7	0
260	Equipercentile linking of the Brief Psychiatric Rating Scale and the Clinical Global Impression Scale in a catchment area. European Neuropsychopharmacology, 2012, 22, 501-505.	0.7	26
261	Delayed- and early-onset hypotheses of antipsychotic drug action in the negative symptoms of schizophrenia. European Neuropsychopharmacology, 2012, 22, 812-817.	0.7	10
262	Patients' acceptance of the deltoid application of risperidone long-acting injection. European Neuropsychopharmacology, 2012, 22, 897-901.	0.7	7
263	Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons. Schizophrenia Bulletin, 2012, 38, 167-177.	4.3	229
264	PHARMACOLOGICAL AUGMENTATION STRATEGIES FOR SCHIZOPHRENIA PATIENTSWITH INSUFFICIENT RESPONSE TO CLOZAPINE. Schizophrenia Research, 2012, 136, S21.	2.0	0
265	META-ANALYSIS ON RELAPSE PREVENTION WITH ANTIPSYCHOTIC DRUGS COMPARED TO PLACEBO IN SCHIZOPHRENIA. Schizophrenia Research, 2012, 136, S58.	2.0	0
266	Poster #216 IS HALOPERIDOL MORE EFFECTIVE THAN OTHER FIRST-GENERATION ANTIPSYCHOTICS IN SCHIZOPHRENIA? A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. Schizophrenia Research, 2012, 136, S263-S264.	2.0	1
267	Early symptom response to antipsychotic medication as a marker of subsequent symptom change: An eighteen-month follow-up study of recent episode schizophrenia. Schizophrenia Research, 2012, 141, 168-172.	2.0	21
268	Maintenance treatment with antipsychotic drugs for schizophrenia. The Cochrane Library, 2012, , CD008016.	2.8	154
269	Critical trial-related criteria in acute schizophrenia studies. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 151-155.	3.2	6
270	Peroxisome proliferator-activated receptor gamma (PPARG) Pro12Ala: lack of association with weight gain in psychiatric inpatients treated with olanzapine or clozapine. Molecular Diagnosis and Therapy, 2012, 16, 93-8.	3.8	7

#	Article	IF	Citations
271	Schizophrenien und andere psychotische StÃ¶rungen. , 2012, , 347-419.		2
272	The clinical significance of cognition-focused interventions for cognitively impaired older adults: a systematic review of randomized controlled trials. International Psychogeriatrics, 2011, 23, 1364-1375.	1.0	66
273	Efficacy of Antimanic Treatments: Meta-analysis of Randomized, Controlled Trials. Neuropsychopharmacology, 2011, 36, 375-389.	5.4	222
274	Proton Magnetic Resonance Spectroscopy and Illness Stage in Schizophreniaâ€"A Systematic Review and Meta-Analysis. Biological Psychiatry, 2011, 69, 495-503.	1.3	126
275	Evidence-based pharmacotherapy of schizophrenia. International Journal of Neuropsychopharmacology, 2011, 14, 269-284.	2.1	87
276	Ventajas y desventajas del tratamiento de combinaciÃ³n con antipsicÃ³ticos. ReuniÃ³n ECNP Consensus, marzo de 2008, Niza. Psiquiatria Biologica, 2011, 18, 55-67.	0.1	2
277	Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials. Schizophrenia Research, 2011, 126, 212-219.	2.0	34
278	Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry, 2011, 10, 138-151.	10.4	631
279	Risperidone versus other atypical antipsychotics for schizophrenia. The Cochrane Library, 2011, , CD006626.	2.8	69
280	Oral versus depot antipsychotic drugs for schizophreniaâ€"A critical systematic review and meta-analysis of randomised long-term trials. Schizophrenia Research, 2011, 127, 83-92.	2.0	397
281	Psychiatristsâ€™ attitude to antipsychotic depot treatment in patients with first-episode schizophrenia. European Psychiatry, 2011, 26, 297-301.	0.2	57
282	Second-generation antipsychotics and constipation: A review of the literature. European Psychiatry, 2011, 26, 34-44.	0.2	113
283	Drowning in Numbersâ€"what Psychiatrists Mean when Talking to Patients about Probabilities of Risks and Benefits of Medication. European Psychiatry, 2011, 26, 130-131.	0.2	2
284	â€œHow to Speak to Your Psychiatristâ€: Shared Decision-Making Training for Inpatients With Schizophrenia. Psychiatric Services, 2011, 62, 1218-1221.	2.0	73
285	How to Obtain NNT from Cohen's d: Comparison of Two Methods. PLoS ONE, 2011, 6, e19070.	2.5	120
286	Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study. BMC Gastroenterology, 2011, 11, 17.	2.0	86
287	Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry, 2011, 10, 52-77.	10.4	1,767
288	Confirmation bias: why psychiatrists stick to wrong preliminary diagnoses. Psychological Medicine, 2011, 41, 2651-2659.	4.5	66

#	Article	IF	Citations
289	Are all antipsychotic drugs the same?. British Journal of Psychiatry, 2011, 199, 269-271.	2.8	11
290	Mid-Term and Long-Term Efficacy and Effectiveness of Antipsychotic Medications for Schizophrenia. Journal of Clinical Psychiatry, 2011, 72, 1616-1627.	2.2	43
291	SpÃtschizophrenie und chronische Schizophrenie im hÃ¶heren Lebensalter. , 2011, , 241-262.		0
292	Quetiapine versus other atypical antipsychotics for schizophrenia. , 2010, , CD006625.		122
293	Zotepine versus other atypical antipsychotics for schizophrenia. , 2010, , CD006628.		10
294	Zotepine versus other atypical antipsychotics for schizophrenia. The Cochrane Library, 2010, , CD006628.	2.8	7
295	Correlation between amygdala volume and age in bipolar disorder â€" A systematic review and meta-analysis of structural MRI studies. Psychiatry Research - Neuroimaging, 2010, 182, 1-8.	1.8	76
296	Methylenedioxymethamphetamine (MDMA). , 2010, , 758-762.		0
297	The PANSS Should Be Rescaled. Schizophrenia Bulletin, 2010, 36, 461-462.	4.3	65
298	Second-generation antipsychotics for anxiety disorders. The Cochrane Library, 2010, , CD008120.	2.8	54
299	Second-generation antipsychotics for major depressive disorder and dysthymia. The Cochrane Library, 2010, , CD008121.	2.8	78
300	Elaboration on the Early-Onset Hypothesis of Antipsychotic Drug Action: Treatment Response Trajectories. Biological Psychiatry, 2010, 68, 86-92.	1.3	55
301	Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis. Schizophrenia Research, 2010, 123, 225-233.	2.0	577
302	Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics Journal, 2010, 10, 20-29.	2.0	90
303	Amisulpride versus other atypical antipsychotics for schizophrenia. The Cochrane Library, 2010, , CD006624.	2.8	26
304	Movement Disorder. , 2010, , 805-805.		0
305	How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed?. European Neuropsychopharmacology, 2010, 20, 276-279.	0.7	26
306	Second-generation antipsychotics for obsessive compulsive disorder. The Cochrane Library, 2010, , CD008141.	2.8	54

#	Article	IF	Citations
307	Clozapine versus other atypical antipsychotics for schizophrenia. The Cochrane Library, 2010, , CD006633.	2.8	130
308	Acamprosate for alcohol dependence. The Cochrane Library, 2010, , CD004332.	2.8	232
309	Olanzapine versus other atypical antipsychotics for schizophrenia. The Cochrane Library, 2010, , CD006654.	2.8	120
310	Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later. Dialogues in Clinical Neuroscience, 2010, 12, 393-407.	3.7	146
311	Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?. Pharmacogenomics Journal, 2009, 9, 395-403.	2.0	45
312	Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials. Schizophrenia Bulletin, 2009, 35, 443-457.	4.3	360
313	A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia. American Journal of Psychiatry, 2009, 166, 152-163.	7.2	453
314	DRD4 48â€‰bp VNTR but not 5-HT2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain. Pharmacogenomics Journal, 2009, 9, 71-77.	2.0	26
315	Cortical Dopamine D2/D3 Receptors Are a Common Site of Action for Antipsychotic Drugs--An Original Patient Data Meta-analysis of the SPECT and PET In Vivo Receptor Imaging Literature. Schizophrenia Bulletin, 2009, 35, 789-797.	4.3	69
316	Evidenceâ€based guidelines for interpretation of the Panic Disorder Severity Scale. Depression and Anxiety, 2009, 26, 922-929.	4.1	120
317	How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Molecular Psychiatry, 2009, 14, 429-447.	7.9	428
318	Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatrica Scandinavica, 2009, 119, 7-14.	4.5	173
319	How to read and understand and use systematic reviews and metaâ€analyses. Acta Psychiatrica Scandinavica, 2009, 119, 443-450.	4.5	49
320	Second-generation antipsychotics for schizophrenia: can we resolve the conflict?. Psychological Medicine, 2009, 39, 1591.	4.5	155
321	Advantages and disadvantages of combination treatment with antipsychotics. European Neuropsychopharmacology, 2009, 19, 520-532.	0.7	125
322	Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet, The, 2009, 373, 31-41.	13.7	1,663
323	Are new drugs for schizophrenia better than old ones? â€“ Authors' reply. Lancet, The, 2009, 373, 1249-1250.	13.7	4
324	Ziprasidone versus other atypical antipsychotics for schizophrenia. The Cochrane Library, 2009, , CD006627.	2.8	45

#	Article	IF	Citations
325	Aripiprazole versus other atypical antipsychotics for schizophrenia. , 2009, , CD006569.		57
326	Sertindole versus other atypical antipsychotics for schizophrenia. The Cochrane Library, 2009, , CD006752.	2.8	13
327	CATIE Findings Revisited. Psychiatric Services, 2009, 60, 125-126.	2.0	5
328	Therapieresistente Schizophrenie (ICD-10 F2). , 2009, , 117-130.		0
329	Schizophrenien und andere psychotische StÃ¶rungen. , 2009, , 411-490.		1
330	Reply to The Importance of Negative Comorbidity. Journal of Clinical Psychiatry, 2009, 70, 1192.	2.2	2
331	An update of meta-analyses on second-generation antipsychotic drugs for schizophrenia. Medical Psychiatry, 2009, , 164-173.	0.2	2
332	Commentary on strategies for switching antipsychotics. BMC Medicine, 2008, 6, 18.	5.5	8
333	Extrapolation between measures of symptom severity and change: An examination of the PANSS and CGI. Schizophrenia Research, 2008, 98, 318-322.	2.0	103
334	Predicting antipsychotic drug response â€“ Replication and extension to six weeks in an international olanzapine study. Schizophrenia Research, 2008, 101, 312-319.	2.0	56
335	Comparative remission rates of schizophrenic patients using various remission criteria. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1643-1651.	4.8	37
336	Identifying the profile of optimal candidates for antipsychotic depot therapy. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1987-1993.	4.8	31
337	Acamprosate supports abstinence, Naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. Journal of Psychopharmacology, 2008, 22, 11-23.	4.0	288
338	Haloperidol versus chlorpromazine for treatment of schizophrenia. Schizophrenia Bulletin, 2008, 34, 813-815.	4.3	9
339	Haloperidol versus chlorpromazine for schizophrenia. The Cochrane Library, 2008, , CD004278.	2.8	39
340	Valproate for schizophrenia. , 2008, , CD004028.		46
341	Personality disorders and violence. Current Opinion in Psychiatry, 2008, 21, 84-92.	6.3	83
342	Dr. Hamann and Colleagues Reply. Journal of Clinical Psychiatry, 2008, 69, 326-327.	2.2	0

#	Article	IF	Citations
343	Cochrane Schizophrenia Group. Schizophrenia Bulletin, 2007, 34, 259-265.	4.3	9
344	Unanswered Questions in Schizophrenia Clinical Trials. Schizophrenia Bulletin, 2007, 34, 302-309.	4.3	24
345	Defining â€˜Responseâ€™ in Antipsychotic Drug Trials: Recommendations for the Use of Scale-Derived Cutoffs. Neuropsychopharmacology, 2007, 32, 1903-1910.	5.4	171
346	Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia. Evidence-Based Mental Health, 2007, 10, 56-56.	4.5	0
347	Different antipsychotics produce similar, small improvements in psychosocial functioning at one year in people with schizophrenia. Evidence-Based Mental Health, 2007, 10, 112-112.	4.5	2
348	Has Research Informed Us on the Practical Drug Treatment of Schizophrenia?. Schizophrenia Bulletin, 2007, 34, 403-405.	4.3	3
349	Benzodiazepines for schizophrenia. , 2007, , CD006391.		61
350	Pretrial Medication Bias in Randomized Antipsychotic Drug Trials. American Journal of Psychiatry, 2007, 164, 1266-1266.	7.2	2
351	Lithium for schizophrenia. , 2007, , CD003834.		55
352	Second-Generation Antipsychotic Agents in the Treatment of Acute Mania. Archives of General Psychiatry, 2007, 64, 442.	12.3	204
353	Methodological Issues in Current Antipsychotic Drug Trials. Schizophrenia Bulletin, 2007, 34, 275-285.	4.3	76
354	Issues in Psychopharmacology. Schizophrenia Bulletin, 2007, 34, 258-258.	4.3	2
355	Review: little evidence to support dose escalation of selective serotonin reuptake inhibitors in non-responders. Evidence-Based Mental Health, 2007, 10, 46-46.	4.5	0
356	The attitude of patients towards antipsychotic depot treatment. International Clinical Psychopharmacology, 2007, 22, 275-282.	1.7	87
357	Carbamazepine for schizophrenia. , 2007, , CD001258.		27
358	Psychiatric treatment guidelines: doctors? non-compliance or insufficient evidence?. Acta Psychiatrica Scandinavica, 2007, 115, 417-419.	4.5	19
359	Physical illness and schizophrenia: a review of the literature. Acta Psychiatrica Scandinavica, 2007, 116, 317-333.	4.5	545
360	On the concept of remission in schizophrenia. Psychopharmacology, 2007, 194, 453-461.	3.1	46

#	Article	IF	Citations
361	Early Prediction of Antipsychotic Nonresponse Among Patients With Schizophrenia. Journal of Clinical Psychiatry, 2007, 68, 352-360.	2.2	118
362	Shared Decision Making and Long-Term Outcome in Schizophrenia Treatment. Journal of Clinical Psychiatry, 2007, 68, 992-997.	2.2	145
363	How long do psychiatrists wait for response before they switch to another antipsychotic?. Psychopharmacology Bulletin, 2007, 40, 149-54.	0.0	0
364	Linking the PANSS, BPRS, and CGI: Clinical Implications. Neuropsychopharmacology, 2006, 31, 2318-2325.	5.4	257
365	Perazine for schizophrenia. , 2006, , CD002832.		2
366	Dr. Hamann and Colleagues Reply. American Journal of Psychiatry, 2006, 163, 937-937.	7.2	0
367	Antidepressants for the negative symptoms of schizophrenia. , 2006, , CD005581.		51
368	Translating research into clinical practice: critical interpretation of clinical trials in schizophrenia. International Clinical Psychopharmacology, 2006, 21, S1-S10.	1.7	5
369	Psychiatric Decision Making in the Adoption of a New Antipsychotic in Germany. Psychiatric Services, 2006, 57, 700-703.	2.0	14
370	Improvement of the physical health of people with mental illness. Current Opinion in Psychiatry, 2006, 19, 411-412.	6.3	11
371	Standardized remission criteria in schizophrenia. Acta Psychiatrica Scandinavica, 2006, 113, 91-95.	4.5	238
372	Eleven-year clinical outcome of schizophrenia in Bali. Acta Psychiatrica Scandinavica, 2006, 114, 68-68.	4.5	0
373	Shared decision making for in-patients with schizophrenia. Acta Psychiatrica Scandinavica, 2006, 114, 265-273.	4.5	265
374	Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation Antipsychotics. American Journal of Psychiatry, 2006, 163, 185-194.	7.2	401
375	The Concepts of Remission and Recovery in Schizophrenia. Pharmacopsychiatry, 2006, 39, 161-170.	3.3	123
376	The Relative Sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in Antipsychotic Drug Trials. Neuropsychopharmacology, 2006, 31, 406-412.	5.4	114
377	Intramuscular haloperidol and olanzapine begin to reduce psychosis within 24 hours. Evidence-Based Mental Health, 2006, 9, 9-9.	4.5	0
378	Serotonin transporter polymorphisms and side effects in antidepressant therapy â€“ a pilot study. Pharmacogenomics, 2006, 7, 159-166.	1.3	57

#	Article	IF	Citations
379	Is the Superior Efficacy of New Generation Antipsychotics an Artifact of LOCF?. Schizophrenia Bulletin, 2006, 33, 183-191.	4.3	185
380	ABCB1 (P-Glycoprotein/MDR1) Gene G2677T/A Sequence Variation (Polymorphism): Lack of Association with Side Effects and Therapeutic Response in Depressed Inpatients Treated with Amitriptyline. Clinical Chemistry, 2006, 52, 893-895.	3.2	56
381	Measurement-Based Psychiatry: Definitions of Response, Remission, Stability, and Relapse in Schizophrenia. Journal of Clinical Psychiatry, 2006, 67, 1813-1814.	2.2	63
382	Attitudes of Psychiatrists Toward Antipsychotic Depot Medication. Journal of Clinical Psychiatry, 2006, 67, 1948-1953.	2.2	132
383	Rapid Detection Of The Intermediate Metabolizer Associated CYP2D6 Polymorphisms *9 And *17 With Real Time PCR. Therapeutic Drug Monitoring, 2005, 27, 242-243.	2.0	0
384	Dr. Correll and Colleagues Reply. American Journal of Psychiatry, 2005, 162, 405-a-406.	7.2	1
385	Perphenazine for schizophrenia. , 2005, , CD003443.		19
386	Benperidol for schizophrenia. The Cochrane Library, 2005, , CD003083.	2.8	4
387	Intermediate Metabolizers And Increased Risk Of Adverse Events in Psychiatric In-patients. an Update Including All Relevant Alleles With Reduced Function and Applying Gene-dose for Analysis. Therapeutic Drug Monitoring, 2005, 27, 254-255.	2.0	0
388	The Dopamine D4 Receptor 48 Base Pair Repeat Polymorphism Influences Antipsychotic Induced Body Weight Gain. A Preliminary Report. Therapeutic Drug Monitoring, 2005, 27, 242.	2.0	1
389	How do psychiatrists choose among different antipsychotics?. European Journal of Clinical Pharmacology, 2005, 61, 851-854.	1.9	14
390	Is there a differential efficacy of new generation antipsychotic drugs?. International Journal of Psychiatry in Clinical Practice, 2005, 9, 154-156.	2.4	0
391	Do Patients With Schizophrenia Wish to Be Involved in Decisions About Their Medical Treatment?. American Journal of Psychiatry, 2005, 162, 2382-2384.	7.2	203
392	Physicians' and Patients' Involvement in Relapse Prevention With Antipsychotics in Schizophrenia. Psychiatric Services, 2005, 56, 1448-1450.	2.0	15
393	Amitriptyline or Not, That Is the Question: Pharmacogenetic Testing of CYP2D6 and CYP2C19 Identifies Patients with Low or High Risk for Side Effects in Amitriptyline Therapy. Clinical Chemistry, 2005, 51, 376-385.	3.2	162
394	Clinical implications of Brief Psychiatric Rating Scale scores. British Journal of Psychiatry, 2005, 187, 366-371.	2.8	799
395	European psychiatric treatment guidelines: is the glass half full or half empty?. European Psychiatry, 2005, 20, 554-558.	0.2	14
396	Early-Onset Hypothesis of Antipsychotic Drug Action: A Hypothesis Tested, Confirmed and Extended. Biological Psychiatry, 2005, 57, 1543-1549.	1.3	218

#	Article	IF	Citations
397	What does the PANSS mean?. Schizophrenia Research, 2005, 79, 231-238.	2.0	1,083
398	Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: A systematic review of randomized trials. Schizophrenia Research, 2005, 80, 85-97.	2.0	81
399	Medical Decision Making in the Mental Health Field. Psychiatric Services, 2005, 56, 221-221.	2.0	4
400	Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies. American Journal of Psychiatry, 2004, 161, 414-425.	7.2	653
401	Allele-Specific Change of Concentration and Functional Gene Dose for the Prediction of Steady-State Serum Concentrations of Amitriptyline and Nortriptyline in CYP2C19 and CYP2D6 Extensive and Intermediate Metabolizers. Clinical Chemistry, 2004, 50, 1623-1633.	3.2	126
402	Amisulpride is an ?atypical? antipsychotic associated with low weight gain. Psychopharmacology, 2004, 173, 112-115.	3.1	42
403	Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials. Schizophrenia Research, 2004, 70, 33-37.	2.0	73
404	Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. Journal of Clinical Epidemiology, 2004, 57, 1124-1130.	5.0	166
405	Language bias in neuroscienceâ€"is the Tower of Babel located in Germany?. European Psychiatry, 2004, 19, 230-232.	0.2	13
406	Medical Decision Making in Antipsychotic Drug Choice for Schizophrenia. American Journal of Psychiatry, 2004, 161, 1301-1304.	7.2	50
407	Amisulpride â€" a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. International Journal of Neuropsychopharmacology, 2004, 7, S15-S20.	2.1	50
408	Lithium for Schizophrenia Revisited. Journal of Clinical Psychiatry, 2004, 65, 177-186.	2.2	55
409	Relationship Between Costs and Symptoms in Schizophrenia Patients Treated With Antipsychotic Medication. Journal of Clinical Psychiatry, 2004, 65, 756-765.	2.2	6
410	Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. Journal of Clinical Psychiatry, 2004, 65, 177-86.	2.2	13
411	Shared decision making in psychiatry. Acta Psychiatrica Scandinavica, 2003, 107, 403-409.	4.5	233
412	New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet, The, 2003, 361, 1581-1589.	13.7	667
413	New generation versus conventional antipsychotics. Lancet, The, 2003, 362, 404-405.	13.7	5
414	Are Patients with Schizophrenia Under-treated with Second-generation Antipsychotics? A Pilot Study of the Prescription Practices of German Psychiatrists. Pharmacopsychiatry, 2003, 36, 309-312.	3.3	8

#	Article	IF	Citations
415	Relapse Prevention in Schizophrenia With New-Generation Antipsychotics: A Systematic Review and Exploratory Meta-Analysis of Randomized, Controlled Trials. American Journal of Psychiatry, 2003, 160, 1209-1222.	7.2	455
416	Are the Second-generation Antipsychotics Cost-effective? A Critical Review on the Background of Different Health Systems. Pharmacopsychiatry, 2003, 36, 18-26.	3.3	27
417	The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. Journal of Clinical Psychiatry, 2003, 64 Suppl 12, 5-19.	2.2	102
418	Amisulpride, an Unusual "Atypical" Antipsychotic: A Meta-Analysis of Randomized Controlled Trials. American Journal of Psychiatry, 2002, 159, 180-190.	7.2	455
419	Carbamazepine Augmentation for Schizophrenia. Journal of Clinical Psychiatry, 2002, 63, 218-224.	2.2	38
420	Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. Clinica Chimica Acta, 2001, 308, 33-41.	1.1	91
421	Doxepin Plasma Concentrations: Is There Really a Therapeutic Range?. Journal of Clinical Psychopharmacology, 2001, 21, 432-439.	1.4	27
422	Dropout rates in randomised antipsychotic drug trials. Psychopharmacology, 2001, 155, 230-233.	3.1	156
423	The Effect of Family Interventions on Relapse and Rehospitalization in Schizophrenia--A Meta-analysis. Schizophrenia Bulletin, 2001, 27, 73-92.	4.3	571
424	Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients. Psychopharmacology, 2000, 147, 378-383.	3.1	38
425	Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research, 1999, 35, 51-68.	2.0	777
426	Results of treatment of schizophrenia: is the glass half full or half empty?. International Clinical Psychopharmacology, 1999, 14, S11-S14.	1.7	21
427	Variability of cerebral blood fow deficits in99mTc-HMPAO SPECT in patients with Alzheimer's disease. Journal of Neural Transmission, 1997, 104, 689-701.	2.8	9
428	Accuracy and reproducibility of the measurement of actively circulating blood volume with an integrated fiberoptic monitoring system. Critical Care Medicine, 1995, 23, 885-893.	0.9	64
429	Monitoring of right ventricular function using a conventional slow response thermistor catheter. Intensive Care Medicine, 1994, 20, 348-353.	8.2	19
430	Opioid antagonists for alcohol dependence. The Cochrane Library, 0, , .	2.8	101
431	Evidence-based pharmacotherapy of schizophrenia. , 0, , 18-38.		1
432	Increasing antipsychotic dose for non response in schizophrenia. The Cochrane Library, 0, , .	2.8	2

#	Article	IF	Citations
433	Antipsychotic dose reduction compared to dose continuation for people with schizophrenia. The Cochrane Library, 0, , .	2.8	2
434	Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia. The Cochrane Library, 0, , .	2.8	1
435	Baseline levels of C-reactive protein and proinflammatory cytokines are not associated with early response to amisulpride in patients with First Episode Psychosis: the OPTiMiSE cohort study. Schizophrenia Bulletin Open, 0, , .	1.7	2